Insiders Indivior PLC

Equities

Market Closed - London S.E. Other stock markets 16:35:23 12/09/2024 BST			5-day change	1st Jan Change
726.50 ^GBX	+1.18%		-20.16%	-38.69%

09-05	Transcript : Indivior PLC Presents at Morgan Stanley 22nd Annual Global Healthcare Conference, Sep-05-2024 10:45 AM
09-04	Indivior reports "disappointing" results for study with Aelis Farma	AN

Indivior PLC Announces Board Committee Changes	05-10	CI
Indivior PLC Appoints David E. Wheadon, M.D. as Independent Non-Executive Director, Effective from June 1, 2024	03-21	CI
Indivior CCO Richard Simkin sells GBP1 million in shares	03-18	AN
Indivior chief commercial officer sells GBP500,000 in shares	03-08	AN
Oxford Nanopore Technologies top team buys shares	03-07	AN
Indivior plans up to USD100 million share buyback programme	11-17	AN
Indivior to keep Scopia's Jerome Lande on board as agreement extended	11-17	AN
Indivior PLC Announces Executive Changes	11-09	CI
Indivior PLC Announces the Changes to the Structure and Composition of Its Board Committees Effective October 1, 2023	29/09/23	CI
Indivior division chief sells GBP1.7 million shares	10/05/23	AN
Indivior PLC Announces Board and Committee Changes	16/02/23	CI
Indivior plc Announces Executive Changes	28/07/22	CI
Indivior Names Nina DeLorenzo Chief Global Impact Officer	16/06/22	CI
Alliance Pharma Chair to Step Down in 2023; Successor Named	18/05/22	MT
Indivior PLC Appoints Barbara Ryan as Independent Non-Executive Director, Effective June 1, 2022	27/04/22	CI
Jerome Lande to Step Down as Member of the Audit Committee of Indivior PLC	25/04/22	CI
Indivior plc Appoints Juliet Thompson as Chair of Audit Committee	09/04/21	CI
Indivior PLC Announces Board Appointments	24/03/21	CI
Indivior PLC Announces Resignation of DanielTassé as Non-Executive Director	11/01/21	CI
Indivior PLC Announces the Appointment of Ryan Preblick as Executive Director	20/11/20	CI

No results for this search